Medical

InCarda Therapeutics has announced the initiation of the Phase 3 RESTORE-1 trial of its InRhythm flecainide inhalation solution in patients with new or recurrent atrial fibrillation. According to InCarda, the FDA has agreed that the… Read more . . .

Revelation Biosciences announced that the Phase 1b CLEAR challenge study of its REVTx-99b intranasal phosphorylated hexaacylated disaccharide (PHAD) in participants with allergies to rye grass pollen showed that the nasal drops were safe and well… Read more . . .

VistaGen Therapeutics said that the PALISADE-1 Phase 3 clinical trial of PH94B aloradine nasal spray for the treatment of anxiety in social anxiety disorder failed to meet its primary endpoint. The company announced the initiation… Read more . . .

CyanVac subsidiary Blue Lake Biotechnology said that dosing has begun in a Phase 1 clinical trial of the company’s BLB-201 intranasal vaccine against respiratory syncytial virus. The open label trial is expected to enroll 15… Read more . . .

Impel Pharmaceuticals said that it has initiated a Phase 2a study of its INP105 intranasal olanzapine in adolescents with autism spectrum disorder, with results expected early next year. In January 2019, Impel (then Impel Neuropharma)… Read more . . .

According to researchers from the Duke Clinical Research Institute (DCRI) and Vanderbilt University, the ACTIV-6 study of repurposed medicines for the treatment of mild-to-moderate COVID-19 has found that inhaled dry powder fluticasone furoate provided no… Read more . . .

Odyssey Health said that a Phase 1 single ascending dose trial of PRV-002 nasal spray, which it describes as “a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion),” has been… Read more . . .

Glenmark Pharmaceuticals and SaNOtize have announced the publication of results from a Phase 3 clinical trial of NONS nitric oxide nasal spray for the treatment of COVID-19 in The Lancet Regional Health Southeast Asia. SaNOtize announced initiation… Read more . . .

Pulmatrix said that the first subjects have been dosed in a Phase 1 trial of the company’s PUR3100 dry powder dihydroergotamine (DHE), which is based on Pulmatrix’s iSPERSE particle engineering platform. The company announced in… Read more . . .